1656
C. Pinedo-Rivilla et al. / Tetrahedron: Asymmetry 22 (2011) 1653–1657
benzylideneindan-1-one 1 (9 mg), and (R)-2-(p-hydroxybenzyl)-7-
75:25, syn 33% ee, anti 42% ee), syn-2-benzyl-2,3-dihydroxyin-
hydroxyindan-1-one 2 (10 mg) (½a D20
ꢀ
¼ ꢁ3:8 (c 0.1, MeOH), 11%
dan-1-one 7 (1.7 mg) ((½a D20
¼ ꢁ17:0 (c 0.1, CHCl3), 26% ee, 100%
ꢀ
ee). Chromatography of the extract fermented for 10 days gave
de), anti-2-benzyl-3-hydroxyindan-1-one
8
(24 mg) ((½a 2D0
¼
ꢀ
(E)-2-benzylideneindan-1-one 1 (10 mg), and (R)-2-(p-hydroxy-
ꢁ38:0 (c 0.1, CHCl3), 100% de, 46% ee), anti-2-benzylindan-1,2-diol
benzyl)-7-hydroxyindan-1-one 2 (15 mg) ((½a D20
ꢀ
¼ ꢁ6:5 (c 0.1,
9 (15 mg) ((½a 2D0
¼ ꢁ15:0 (c 0.1, CHCl3), 100% de, 18% ee), 3-hydro-
ꢀ
MeOH), 19% ee). (b) Shaken culture. (E)-2-Benzylideneindan-1-one
1 was dissolved in ethanol and then distributed in 10 flasks
(500 mL) in an orbital shaker after 2 days growth. The fermenta-
tion was allowed to continue for 5 more days in five of the flasks
and 10 more days in the other five. Chromatography of the extract
fermented for 5 days gave (E)-2-benzylideneindan-1-one 1 (4 mg),
xy-2-(hydroxyphenylmethyl)indan-1-one 10 (8 mg) ((½a D20
¼
ꢀ
ꢁ50:6 (c 0.1, CHCl3), 100% de, 60% ee), and 2-hydroxy-2-(hydroxy-
phenylmethyl)indan-1-one 11 (2 mg) ((½a D20
ꢀ
¼ ꢁ28:0ꢂ (c 0.1,
CHCl3), 100% de, 98% ee). Chromatography of the extract fermented
for 15 days gave (E)-2-benzylideneindan-1-one 1 (9 mg), (S)-2-
benzylindan-1-one (S)-4 (10 mg) (½a D20
¼ þ23:5 (c 0.1, CHCl3),
ꢀ
and (R)-2-(p-hydroxybenzyl)-7-hydroxyindan-1-one
2
(17 mg)
10% ee), (1S,2R)-2-benzylindan-1-ol (1S,2R)-5 (5 mg) ((½a D20
¼
ꢀ
((½a 2D0
ꢀ
¼ ꢁ4:0 (c 0.1, MeOH), 12% ee). Chromatography of the ex-
ꢁ11:0 (c 0.1, CHCl3), 95% ee), (1R,2R)-2-benzylindan-1-ol (1R,2R)-
5 (traces), syn-2-(hydroxylphenylmethyl)indan-1-one 6 (traces),
tract fermented for 10 days gave (E)-2-benzylideneindan-1-one 1
(14 mg), and (S)-2-(p-hydroxybenzyl)indan-1-one
3
(50 mg)
anti-2-benzyl-3-hydroxyindan-1-one 8 (30 mg) ((½a D20
¼ ꢁ15:6 (c
ꢀ
((½a 2D0
ꢀ
¼ þ6:0 (c 0.1, MeOH), 36% ee).
0.1, CHCl3), 100% de, 19% ee), anti-2-benzylindan-1,2-diol 9
(8 mg) ((½a 2D0
¼ ꢁ7:07.0 (c 0.1, CHCl3), 100% de, 7% ee), 2-hydro-
ꢀ
4.4.2. Biotransformation by T. viride
xy-2-(hydroxyphenylmethyl)indan-1-one 11 (5 mg) ((½a D20
¼ ꢁ6:4
ꢀ
(a) Surface culture. (E)-2-Benzylideneindan-1-one 1 was dis-
solved in ethanol and then distributed in 12 Roux bottles after
2 days growth. The fermentation was allowed to continue for 5
more days in six of the bottles and 10 more days in the other six.
Chromatography of the extract fermented for 5 days gave (E)-2-
benzylideneindan-1-one 1 (16 mg), (R)-2-benzylindan-1-one (R)-
(c 0.1, CHCl3), 100% de, 22% ee), and (E)-2-benzylidene-3-hydrox-
yindan-1-one 12 (1.5 mg) ((½a D20
¼ þ62:5 (c 0.1, CHCl3), 95% ee).
ꢀ
4.5. Oxidation of (1R,2R)-2-benzylindan-1-ol (1R,2R)-5
The alcohol (1R,2R)-2-benzylindan-1-ol (1R,2R)-5 (5 mg,
0.022 mmol) was oxidised with manganese(IV) oxide (1.5 equiv)
in methylene chloride solution (1.5 mL) at room temperature. After
purification using a silica gel column, eluting with hexane/ethyl
acetate (9:1), the derivative (R)-(ꢁ)-2-benzylindan-1-one (R)-4
(98% yield) was afforded.
4 (2 mg) ((½a 2D0
¼ ꢁ197:1 (c 0.1, CHCl3), 86% ee), and syn-2-benzy-
ꢀ
lindan-1-ol 5 (traces). Chromatography of the extract fermented
for 10 days gave (E)-2-benzylideneindan-1-one 1 (2 mg), (R)-2-
benzylindan-1-one (R)-4 (3 mg) ((½a D20
¼ ꢁ162:0 (c 0.1, CHCl3),
ꢀ
70% ee), and syn-2-benzylindan-1-ol 5 (traces). (b) Shaken culture.
(E)-2-Benzylideneindan-1-one 1 was dissolved in ethanol and then
distributed in 10 flasks (500 mL) in an orbital shaker after 2 days
growth. The fermentation was allowed to continue for 5 more days
in five of the flasks and 10 more days in the other five. Chromatog-
raphy of the extract fermented for 5 days gave (E)-2-benzyliden-
eindan-1-one 1 (22 mg), (R)-2-benzylindan-1-one (R)-4 (3.5 mg)
4.5.1. (R)-2-(p-Hydroxybenzyl)-7-hydroxyindan-1-one 26
Obtained as a yellow oil, (½a D20
¼ ꢁ6:5 (c 0.1, MeOH), 19% ee.
ꢀ
HPLC (n-hexane/i-PrOH 97:3, 0.5 mL/min): tR 30.1 min (R) and
50.9 min (S).
((½a 2D0
ꢀ
¼ ꢁ179:0 (c 0.1, CHCl3), 78% ee), and (1R,2R)-2-benzylin-
4.5.2. (S)-2-(p-Hydroxybenzyl)indan-1-one 3
dan-1-ol (1R,2R)-5 (3 mg) (½a D25
ꢀ
¼ ꢁ5:0ꢂ (c 0.1, CHCl3), 100% de,
Obtained as a yellow oil, (½a D20
¼ þ6:0 (c 0.1, MeOH), 36% ee. IR
ꢀ
99% ee). Chromatography of the extract fermented for 10 days gave
mmax (film): 3344, 1688. 1H NMR (400 MHz, CD3OD): d 2.70 (ddd,
1H, J = 2.0, 9.7, 13.8 Hz, H-10), 2.82 (dt, 1H, J = 3.2, 16.9 Hz, H-3),
2.99 (m, 1H, H-2), 3.09 (dd, 1H, J = 7.3, 16.9 Hz, H-3), 3.19 (dd, 1H,
(E)-2-benzylideneindan-1-one 1 (3 mg), (S)-2-benzylindan-1-one
(S)-4 (20 mg) ((½a D20
¼ þ37:1 (c 0.1, CHCl3), 16% ee), (1R,2R)-2-ben-
ꢀ
zylindan-1-ol (1R,2R)-5 (8 mg) ((½a D20
ꢀ
¼ ꢁ4:0 (c 0.1, CHCl3), 79%
´
´
J = 4.4, 13.8 Hz, H-10), 6.66 (d, 2H, J = 8.5 Hz, H-3, H-5), 6.67 (m,
ee), and (1S,2R)-2-benzylindan-1-ol (1S,2R)-5 (2 mg) ((½a D20
ꢀ
¼
1H, H-4), 7.02 (m, 1H, H-5), 7.03 (d, 2H, J = 8.5 Hz, H-2, H-6), 7.08
(dt, 1H, J = 3.2, 8.2 Hz, H-6), 7.27 (dd, 1H, J = 3.5, 8.2 Hz, H-7). 13C
NMR (100 MHz, CD3OD): d 32.1 (t, C-3), 37.2 (t, C-10), 51.2 (d, C-2),
´
´
ꢁ7:2 (c 0.1, CHCl3), 64% ee).
´
´
108.9 (d, C-5), 116.2 (d, C-3, C-5), 121.2 (d, C-4), 125.1 (d, C-6),
4.4.3. Biotransformation by Eutypa lata
´
´
´
(a) Surface culture. (E)-2-Benzylideneindan-1-one 1 was dis-
solved in ethanol and then distributed in 12 Roux bottles after
7 days growth. The fermentation was allowed to continue for 8
more days in six of the bottles and 15 more days in the other six.
Chromatography of the extract fermented for 8 days gave (E)-2-
128.5 (d, C-7), 130.9 (d, C-2, C-6), 131.5 (s, C-1), 146.9 (s, C-9),
+
´
156.9 (s, C-4), 158.5 (s, C-8), 210.7 (s, C-1). MS (m/z, %): 238 (M ,
0.3), 148 (33), 107 (100), 77 (15). HRMS (EI, 70 eV): calcd for
C
16H14O2: 238.09938 [M]+; found: 238.0971. HPLC (n-hexane/i-
PrOH 97:3, 0.5 mL/min): tR 21.9 min (R) and 33.9 min (S).
benzylideneindan-1-one
(traces) and anti-2-benzylindan-1,2-diol
1
(36.3 mg), 2-benzylindan-1-one
4
¼
9
(1.2 mg) ((½a 2D0
ꢀ
4.5.3. 2-Benzylindan-1-one 4
ꢁ14:0 (c 0.1, CHCl3), 100% de, 16% ee). Chromatography of the ex-
tract fermented for 15 days gave (E)-2-benzylideneindan-1-one 1
Obtained as a colourless oil. Product structure assignments
were done attending to the spectroscopic data reported in the lit-
erature.5 HPLC (n-hexane/i-PrOH 9:1, 0.4 mL/min): tR 17.0 min (R)
and 18.4 min (S).
(34.3 mg), (R)-2-benzylindan-1-one (R)-4 (3 mg) ((½a D20
¼ ꢁ48:6
ꢀ
(c 0.1, CHCl3), 21% ee), and anti-2-benzylindan-1-ol 5 (traces). (b)
Shaken culture. (E)-2-Benzylideneindan-1-one 1 was dissolved in
ethanol and then distributed in 10 flasks (500 mL) in an orbital
shaker after 7 days growth. The fermentation was allowed to con-
tinue for 8 more days in five of the flasks and 15 more days in the
other five. Chromatography of the extract fermented for 8 days
gave (E)-2-benzylideneindan-1-one 1 (23 mg), (R)-2-benzylindan-
4.5.4. 2-Benzylindan-1-ol 5
Obtained as a white solid. Product structure assignments were
done attending to the spectroscopic data reported in literature.7
HPLC (n-hexane/i-PrOH 9:1, 0.4 mL/min): tR (anti): 14 min (S,R)
and 30 min (R,S); tR (syn): 18.7 min (R,R) and 23.1 min (S,S).
1-one (R)-4 (15 mg) ((½a D20
¼ ꢁ166:3 (c 0.1, CHCl3), 72% ee),
ꢀ
(1S,2R)-2-benzylindan-1-ol (1S,2R)-5 (1.8 mg) ((½a D20
ꢀ
¼ ꢁ11:0 (c
4.5.5. syn-2-(Hydroxyphenylmethyl)indan-1-one 6
0.1, CHCl3), 100% de, 95% ee), syn-2-(hydroxylphenylmeth-
Obtained as a colourless oil, (½a D20
¼ þ88:0 (c 0.1, CHCl3), syn/
ꢀ
yl)indan-1-one 6 (3 mg) ((½a D20
ꢀ
¼ þ88:0 (c 0.1, CHCl3), syn/anti
anti 75:25, syn 33% ee, anti 42% ee as determined by 1H NMR spec-